3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Genitourinary
1
CNS
1
Conditions
Recurrence
3
Neoplasms
3
Glioma
3
Triple Negative Breast Neoplasms
2
Sarcoma
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Wilms Tumor
1
Waldenstrom Macroglobulinemia
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Prostatic Neoplasms
1
Paraproteinemias
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms, Plasma Cell
1
Neoplasms, Neuroepithelial
1
Medulloblastoma
1
Lymphoproliferative Disorders
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Immunoproliferative Disorders
1
Hodgkin Disease
1
Interventions
Pemetrexed
3
mifamurtide
2
lenvatinib
2
dostarlimab
2
belinostat
2
Ifosfamide
2
Granulocyte-Macrophage Colony-Stimulating Factor
2
Gemcitabine
2
Etoposide
2
Drug Therapy
2
Cyclophosphamide
2
Cisplatin
2
vactosertib
1
surufatinib
1
sintilimab
1
robatumumab
1
ridaforolimus
1
reolysin
1
pembrolizumab
1
pazopanib
1
omburtamab I-131
1
niraparib
1
isophosphamide mustard
1
fludarabine
1
endostar protein
1
dinutuximab
1
copanlisib
1
cc-486
1
cabozantinib
1
anlotinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Osteosarcoma
×
CLR1404
×
Clear all
NCT03478462
2026-03-18
CLOVER-2
Cellectar Biosciences, Inc.
Phase 1
Active not recruiting
30 enrolled